With a base of over 80,000 patients across 14 states in the U.S., CB2 Insights Inc. (CBII:CSE) focuses on standardized data collection of clinical trial protocols for medical cannabis industry.  CEO Prad Sekar tells how the recent acquisition of Relax Clarity in Colorado could help filling the gap between crowd sourced anecdotal data and the lack of clinical trials within the medical cannabis space.   By gathering data and creating objective real-world evidence through proprietary software and clinical service brands, the company hopes to mainstream cannabis into traditional healthcare.

CB2 Insights (CSE:CBII) CEO Prad Sekar joined Steve Darling from Proactive Investors Vancouver to discuss yet another acquisition by the Toronto based company. CB2 buying Colorado-based Relaxed Clarity in a combined stock and cash deal.   Sekar telling Proactive why they decided to do this deal and how this sets them up to reach a major revenue milestone.

CB2 Insights (CSE:CBII) CEO Prad Sekar joined Steve Darling from Proactive Investors Vancouver on Skype from Toronto to share news the company has signed an agreement with the British Columbia based Premier Health Group to use the industry’s only medical cannabis-specific Clinical Decision Support tool.   This deal gives CB2 access to 4600 physicians and data gathered from over 300 thousand patients.

CB2 Insights (CBII) CEO Prad Sekar joined Steve Darling from proactive Investors on Skype to discuss CB2’s acquisition of MedEval Clinic LLC, a medical cannabis evaluation and education center group with multiple locations in Colorado and Arizona.  Sekar discussed why they decided to do the deal and how it fits in the overall strategy at CB2. Sekar also addressed the clinics model and revenue expected to be generated.

CB2 Insights CEO Prad Sekar: 

CB2 Insights (CSE:CBII) CEO Prad Sekar joined Steve Darling from Proactive Investors Vancouver from Toronto to discuss the company going public. CB2 is now listed on the Canadian Securities Exchange under the ticker CBII.  Sekar told Proactive just how big this is for the company and also how they plan on using the 5.7 million dollars they have currently raised .

CB2 Insights (CNSX:CBII) is a predictive analytics, software, and services company operating in the medical cannabis space. CEO Prad Sekar is excited about the company’s launch on the CSE and believes it is another step in achieving the company’s mission of mainstreaming medical cannabis. Sekar sees cannabis becoming a hallmark medication. The company’s technology allows point-of-care data gathering, which will provide the next level of validation for medical cannabis. CB2 Insights operates in 12 states and has 60,000 patient interactions per year. CB2 Insights  completed a $5 million non-brokered private placement prior to going public to continue its execution plan and for further acquisitions and consolidation.

In this interview at the recent Cantech Investment Conference 2019 in Toronto, SmallCapPower spoke with Prad Sekar, CEO of CB2 Insights Inc, about the Company’s mission to use data sets and business intelligence to educate the medical community about the use of cannabis, as well as its efficacy and role within a patient’s treatment plan. Watch our short video to find out how CB2 Insights plans to adopt an aggressive acquisition strategy in 2019 as well as list on the Canadian Securities Exchange.

The FDA is changing how real world evidence is used in the pharmaceutical industry so that data collected outside clinical trials has become massively valuable. CB2 Insights' 28 clinics see 65,000 active uniques patients per year and are focused solely on cannabis medicine. CB2 Insights collects controlled data from those clinics using their proprietary technology and is applying predictive analytics to reveal the value in that data.   Presenting in this video is Prad Sekar, CEO of CB2 Insights.

Prad Sekar, CEO of CB2 Insights, explains the technology behind his company’s innovations and discusses plans to go public this year.